Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA ().
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL ().Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. . Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M ().
0 kommentar(er)
